Skip to Content

Gleevec (imatinib) Disease Interactions

There are 7 disease interactions with Gleevec (imatinib):

Moderate

BCR-ABL tyrosine kinase inhibitors (Includes Gleevec) ↔ cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease

Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors. If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention. The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.

Moderate

BCR-ABL tyrosine kinase inhibitors (Includes Gleevec) ↔ fluid retention

Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Pleural Effusion, Fluid Retention

Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure. Monitor and manage patients using standards of care. Interrupt, reduce dose or discontinue therapy as necessary.

Moderate

BCR-ABL tyrosine kinase inhibitors- bone marrow suppression

Moderate Potential Hazard, Moderate plausibility. Applies to: Bone Marrow Depression/Low Blood Counts

Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors. Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression. A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated. To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.

Moderate

Imatinib (Includes Gleevec) ↔ gastrointestinal disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Perforation, Duodenitis/Gastritis

Imatinib has been sometimes associated with GI irritation, and it should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of gastrointestinal perforation. Caution should be used in patients with history of GI disorders.

Moderate

Imatinib (Includes Gleevec) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Patients with severe hepatic impairment tend to have higher exposure to both imatinib and its metabolite than patients with normal hepatic function, and dose might need to be adjusted accordingly. Additionally, there have been reports of hepatotoxicity both with short and long term use of imatinib. Liver function should be monitored before initiation of treatment and regularly during therapy. Dose reduction or interruption might be needed if laboratory abnormalities are found.

Moderate

Imatinib (Includes Gleevec) ↔ hypothyroidism

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypothyroidism

Hypothyroidism cases have been reported in thyroidectomy patients undergoing levothyroxine replacement therapy during treatment with imatinib. Caution should be used in these patients and TSH levels should be monitored closely.

Moderate

Imatinib (Includes Gleevec) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The mean exposure to imatinib is increased in patients with renal impairment compared to those with normal renal function. Dose reductions are necessary in patients with moderate and severe renal impairment.

Gleevec (imatinib) drug interactions

There are 924 drug interactions with Gleevec (imatinib)

Gleevec (imatinib) alcohol/food interactions

There is 1 alcohol/food interaction with Gleevec (imatinib)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide